A Post-market Registry of the MARIS-stent (Invatec) Implanted in the Superficial Femoral Artery
NCT ID: NCT01067885
Last Updated: 2012-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1051 participants
INTERVENTIONAL
2006-04-30
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective, Post Market Surveillance Q3-registry (POLARIS)
NCT02307292
Safety and Effectiveness Study of EverFlex Stent to Treat Symptomatic Femoral-popliteal Atherosclerosis
NCT00530712
The Study to Treat Superficial Femoral Artery Occlusions.
NCT00232843
DURABILITY+ : a Prospective, Multi-center, Controlled Study With the Everflex+ Stent in SFA Lesions
NCT01412463
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions
NCT01327950
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose of the Maris Register is to evaluate the primary nitinol stent implantation in an all comer population with diseased SFA.
The MARIS Register is a prospective, multicenter registry of the implantation of at least one at most five nitinol stents (Maris / Invatec) in the SFA without limitations for stenosis or occlusion length.
The registry includes 998 patients from 13 German investigational sites. Clinical data are captured on electronic case report forms
The primary endpoint is the target lesion revascularization after 12 month
Secondary endpoints are :
* Restenosis rate \> 50% according to ultrasound criteria
* Restenosis rate \> 70% according to ultrasound criteria
* Location of restenosis (proximal, middle, distal AFS)
* Number of stent fractures (grading according to FESTO criteria)
* Procedure related complication rate
* Vascular complication rate within 12 month
* Amputations within 12 month
* Deaths within 12 month
In order to measure the restenosis the peak systolic velocity (PSV) is to be measured in two sections during the duplex ultrasound examinations at 6 and 12 month. First measurement is performed 2cm proximal to the first stent, second measurement at the location where the maximum peak velocity over all lesions/all implanted stents is measured.
The clinical status includes the patient´s Fontaine classification.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MARIS-stent (Invatec)
stenting of SFA with Maris nitinol stent/s
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* existing SFA stenosis 70-100 % (visual estimation)
* absence of homodynamically relevant stenosis in A. poplitea
* at least one lower limb run off vessel
Exclusion Criteria
* life expectancy less than 1 year
* coagulation disorder
* chronic anticoagulation therapy
* active gastrointestinal bleeding
* thrombolytic therapy within 72 hours before intervention
* hyperthyreosis
* severe contrast agent allergy
* allergy to concomittant medication
* severe liver disease
* thrombus in target lesion
* target lesion extend into A. poplitea
* severe calcification of target vessel, where no successful pre-dilatation is feasible
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic Vascular
INDUSTRY
Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hans Krankenbeg, MD
Role: PRINCIPAL_INVESTIGATOR
MCC Prof. Mathey, Prof. Schofer
References
Explore related publications, articles, or registry entries linked to this study.
Krankenberg H, Tubler T, Sixt S, Fischer M, Schmiedel R, Schulte KL, Balzer JO, Kieback A, Fiehn E, Wittenberg G, Ali T, Tiefenbacher C, Jahnke T, Steinkamp HJ, Wegscheider K, Treszl A, Ingwersen M, Zeller T. German multicenter real-world registry of stenting for superficial femoral artery disease: clinical results and predictive factors for revascularization. J Endovasc Ther. 2014 Aug;21(4):463-71. doi: 10.1583/13-4625R.1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MARIS-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.